HemaCare Co. (OTCMKTS:HEMA – Get Free Report) traded up 0.6% during trading on Monday . The company traded as high as $25.31 and last traded at $25.31. 5,400 shares were traded during mid-day trading, a decline of 86% from the average session volume of 39,950 shares. The stock had previously closed at $25.16.
HemaCare Stock Up 0.6%
The stock’s fifty day simple moving average is $25.31 and its 200 day simple moving average is $25.31.
HemaCare Company Profile
HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.
In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers.
Recommended Stories
- Five stocks we like better than HemaCare
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.
